UBS raised the firm’s price target on AnaptysBio (ANAB) to $20 from $18 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
- AnaptysBio price target raised to $45 from $40 at Wedbush
- Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
- AnaptysBio Reports Q2 2025 Financial Results and Updates
- AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating